Tyra Biosciences, Inc.
TYRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. At a $1.71B market cap, Tyra Biosciences, Inc. ranks as a small-cap company within healthcare. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Market Cap
$1.71B
Beta
0.73
P/E (TTM)
—
P/E (Fwd)
-9.67
EPS (TTM)
$-2.39
EPS (Fwd)
$-2.96
ROE
-45.3%
ROA
-28.5%
Cash
$353.9M
Total Debt
$5.6M
Free CF
-$63.1M
52W Change
142.4%
Annual Financials
Cash vs Debt
Where TYRA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, TYRA finished 18.75% below its 150-day moving average ($32.16) and 12.90% below its 200-day moving average ($30.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TYRA overbought or oversold?
At the August 28, 2026 close, TYRA's RSI(14) was 47.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $353.9M in cash comfortably exceeding the $5.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$63.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -45.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, TYRA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TYRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.